New Insulin Grown in the Ground Equivalent to Commercial Insulin

Plant-produced insulin has been demonstrated in animal models to be chemically, structurally and functionally equivalent to U.S. pharma grade human insulin. SemBioSys Genetics Inc., a biotechnology company developing a broad pipeline of protein-based pharmaceuticals and non-pharmaceutical products, announced that its proprietary plant-produced insulin has been demonstrated in animal models to be chemically, structurally and functionally equivalent to U.S. pharma grade human insulin. The results of analytical, in vitro and in vivo assays confirm that insulin produced in safflower, SemBioSys’ commercial crop, is indistinguishable from human insulin analytically and physiologically.

As a result of these achievements SemBioSys expects to submit an Investigational New Drug Application (IND) later this year and initiate a Pharmacokinetic/Pharmacodynamic study of safflower-produced insulin late in the fourth quarter of 2007.
SemBioSys has demonstrated functional equivalence through conducting insulin tolerance testing in mice, which monitors blood glucose levels as the assay variable, confirming that there is no statistically significant difference in the pharmacodynamic response of safflower-produced insulin in comparison to Eli Lilly’s Humulin® treatments.

Demand for insulin for the treatment of diabetes reached an estimated 5,000 to 6,000 kilograms in 2005 and is projected to increase to 16,000 kilograms by 2012. Demand for insulin is expected to grow due to a number of issues including; earlier diagnosis of diabetes; increased diabetes incidence in the developed world due to demographic trends, as well as consumption and behavioural habits; increasing incidence in the developing world due to increasing affluence and changing dietary habits; new alternative delivery methods that require between five and ten times the amount of insulin as injection methods; and the use of insulin as a treatment for type 2 diabetes patients earlier in the treatment protocol as recommended by the consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.

SemBioSys believes its safflower-produced insulin can reduce capital costs compared to existing insulin manufacturing by up to 70% and product costs by 40% or more. Insulin currently produced using fermentation is estimated to require $200 to $250 million in capital investment for 1,000 kilograms of production capacity. In addition, because of the ease in scaling-up crop acreage, plant-produced insulin offers significant improvements in the flexibility and speed of scale-up. SemBioSys has five years of experience growing transgenic safflower in Canada, the U.S., Mexico and Chile under permits issued by the pertinent regulatory authorities.

www.sembiosys.com. webcast

====================================================

Advertisement:
Breaking News from the American Diabetes Association 66th Scientific Sessions
Did you miss the ADA Scientific Sessions in Washington, DC? Get up to speed on the latest research and updates to current knowledge on diabetes and dyslipidemia-FREE CME Activities from the ADA Scientific Sessions are now available! Click here to access the interactive CME newsletter summary of several presentations relevant to clinical practice and the CME case-based slide and audio presentations on the real-world management of patients with diabetes and dyslipidemia recorded at the ADA meeting. Don’t miss this opportunity to learn the latest clinical updates from one of the year’s most critical diabetes events!
https://www.cemedicus.com/diabetes